Academic
Publications
Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?

Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?,10.1038/bmt.2008.13,Bone Marrow Transplantation,S Chunduri,L C Dob

Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?   (Citations: 7)
BibTex | RIS | RefWorks Download
In this study, we utilized a conditioning regimen with fludarabine and myeloablative dose i.v. BU (12.8 mg/kg) (FluBU) in 36 adult patients (median age: 44 years, range: 18–61) with myeloid or lymphoid malignancies at standard risk (n=10) or high risk of relapse (n=26), who received an allogeneic hematopoietic SCT (HSCT) from HLA-matched related (n=16) or unrelated (n=20) donors. The source of hematopoietic stem cells was peripheral blood in 28 and marrow in 8 cases. Rabbit-antithymocyte globulin at 7 mg/kg was utilized in 21 patients. Acute GVHD grade II–IV was observed in 19% of the patients (grade III–IV in 14% of patients) and chronic GVHD in 11 of 30 evaluable patients (37%). At median follow-up of 737 days (range: 152–1737) for alive patients, overall survival rates in standard- and high-risk patients were 80 and 35%, respectively, and event-free survival rates were 70 and 31%, respectively. TRM was 10% in standard-risk and 19% in high-risk patients. Post transplant relapse was observed in 20% standard-risk and in 46% high-risk patients. FluBU conditioning regimen is associated with a limited hematologic and extrahematologic toxicity and with an antitumor activity comparable to other standard myeloablative regimens.
Journal: Bone Marrow Transplantation - BONE MARROW TRANSPLANT , vol. 41, no. 11, pp. 935-940, 2008
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
Sort by: